Company: LNAI
Filing Date: 2025-02-19
Form Type: 10-K/A
Source: 0001731122-25-000252
Chunk: 79

Company: Lunai Bioworks Inc.
Filing Date: 2025-02-19
Form: 10-K/A
Chunk 79
---
ovaro Cube’s products, could subject Renovaro Cube to product liability or professional liability claims. A product
liability or professional liability claim against Renovaro Cube could result in substantial damage and be costly and time-consuming to
defend. Any liability claim brought against Renovaro Cube, with or without merit, could increase its insurance rates or prevent it from
securing insurance coverage in the future. Additionally, any liability lawsuit could damage Renovaro Cube’s reputation or force
it to delay or suspend sales of its products. The occurrence of any of these events could have a material adverse effect on Renovaro Cube’s
business, results of operations, financial condition and prospects.

Risks Related to our Common Stock

Our stock price has been and will likely continue to be volatile and may decline regardless of our operating performance.

Our stock price has fluctuated in the past and can be expected to be volatile
in the future. From October 2, 2023, through October 2, 2024, the reported sale price of our Common Stock has fluctuated between $5.18
and $0.46 per share. The stock market in general and the market for biotechnology and technology companies in particular have experienced
extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility,
investors may experience losses on their investment in our Common Stock. The market price of our Common Stock may be influenced by many
factors, including the following:

| ● | negative publicity;                                                                               |
| ● | our compliance with Nasdaq                                                                        
 rules and regulations;                                                                            |
| ● | the success of competitive                                                                        
 products or technologies;                                                                         |
| ● | regulatory actions with                                                                           
 respect to our product candidates or products or our competitors’ product candidates or products; |

| ● | actual or anticipated changes                                                                                                
 in our growth rate relative to our competitors;                                                                              |
| ● | announcements by us or                                                                                                       
 our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations, or capital commitments; |
| ● | results                                                                                                                      
 of clinical studies of our product candidates or those of our competitors;                                                   |
| ● | regulatory                                                                                                                   
 or legal developments in the U.S. and other countries;                                                                       |
| ● | developments                                                                                                                 
 or disputes concerning patent applications, issued patents or other proprietary rights;                                      |
| ● | the                                                                                                                          
 recruitment or departure of key personnel;                                                                                   |
| ● | the level of expenses related